MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Sage Therapeutics Inc

Suletud

SektorTervishoid

7.85 -1.13

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.71

Max

7.95

Põhinäitajad

By Trading Economics

Sissetulek

-2.2M

-96M

Müük

945K

13M

Aktsiakasum

-1.197

Kasumimarginaal

-747.331

Töötajad

353

EBITDA

21M

-80M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+3.14% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

24. apr 2025

Turustatistika

By TradingEconomics

Turukapital

505M

Eelmine avamishind

8.98

Eelmine sulgemishind

7.85

Uudiste sentiment

By Acuity

100%

0%

370 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Sage Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. apr 2025, 23:15 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

1. apr 2025, 23:46 UTC

Market Talk

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

1. apr 2025, 23:43 UTC

Market Talk

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

1. apr 2025, 23:11 UTC

Peamised uudised

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

1. apr 2025, 23:02 UTC

Market Talk

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

1. apr 2025, 22:31 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 22:26 UTC

Market Talk

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

1. apr 2025, 21:47 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 21:32 UTC

Peamised uudised

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

1. apr 2025, 21:06 UTC

Market Talk

Mexican Remittances See Slow Start to the Year -- Market Talk

1. apr 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

1. apr 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

1. apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. apr 2025, 20:47 UTC

Peamised uudised

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

1. apr 2025, 20:47 UTC

Peamised uudised

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

1. apr 2025, 20:20 UTC

Peamised uudised

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1. apr 2025, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Fibrebond >ETN

1. apr 2025, 20:11 UTC

Market Talk

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

1. apr 2025, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1. apr 2025, 20:00 UTC

Peamised uudised

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

1. apr 2025, 19:46 UTC

Peamised uudised

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

1. apr 2025, 19:43 UTC

Market Talk

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

1. apr 2025, 19:17 UTC

Peamised uudised

Meta's Head of AI Research to Resign Amid Computing Push -- Update

1. apr 2025, 19:13 UTC

Market Talk

U.S. Natural Gas Futures Give Back Gains -- Market Talk

1. apr 2025, 19:03 UTC

Market Talk

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

1. apr 2025, 19:00 UTC

Market Talk

Gold Slips Ahead of Tariff Day -- Market Talk

1. apr 2025, 18:54 UTC

Market Talk

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Sage Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

3.14% tõus

12 kuu keskmine prognoos

Keskmine 8.2 USD  3.14%

Kõrge 12 USD

Madal 5 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Sage Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

17 ratings

2

Osta

14

Hoia

1

Müü

Tehniline skoor

By Trading Central

7.94 / 8.22Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.